Mangalam Drugs & Organics (NSE:MANGALAM) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
43 GF Score
Price ₹27.59
GF Value ₹62.70
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Mangalam Drugs & Organics Quality Rank Related Terms

NSE:MANGALAM
43GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹27.59 is trading 56% below its estimated GF Value™ of ₹62.70. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Quality Rank:
  • GF Value™: ₹62.70 vs. price of ₹27.59 (56% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score

Get the complete analysis for NSE:MANGALAM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹27.59
Price
₹62.70
GF Value